Breaking Finance News

Zacks Investment Research issued a report on Vernalis plc (ADR) (NASDAQ:VNLPY), raising its target price to $0.50 today

In a report released on Wednesday June 21, 2017 Zacks Investment Research upped the target of Vernalis plc (ADR) (NASDAQ:VNLPY) to $0.50 stating a potential downside of -0.14%.

Boasting a price of $0.58, Vernalis plc (ADR) (NASDAQ:VNLPY) traded 3.57% higher on the day. With the last stock price close down 0.41% from the two hundred day average, compared with the S&P 500 Index which has increased 0.04% over the date range. Vernalis plc (ADR) has recorded a 50-day average of $0.58 and a two hundred day average of $0.58. Volume of trade was down over the average, with 0 shares of VNLPY changing hands under the typical 75

Performance Chart

Vernalis plc (ADR) (NASDAQ:VNLPY)

With a total market value of $0, Vernalis plc (ADR) has 52 week low of $0.47 and a 52 week high of $0.95 .

General Information About Vernalis plc (ADR) (NASDAQ:VNLPY)

Vernalis plc is a commercial-stage pharmaceutical company. The Company is engaged in the research, development and commercialization of pharmaceutical products. The Company operates through two segments: Commercial, which covers all areas relating to the commercial sale of pharmaceutical products, the manufacture and distribution directly related to that activity, and Research and Development, which includes all activities related to the research and development of pharmaceutical products for a range of medical disorders. The Company markets three products, including Tuzistra XR in the United States prescription cough cold market; Moxatag, which is a once daily amoxicillin approved in the United States for tonsillitis and pharyngitis, and frovatriptan, which is an acute treatment for migraine. The Company also has four over prescription cough cold products under development and a pipeline of new chemical entity (NCE) development programs and research collaborations.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *